Does Rallies show Form 4 insider transactions for RZLT?

Yes. Rallies tracks RZLT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RZLT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RZLT. It does not provide personalized investment advice.

RZLT (Rezolute, Inc. Common Stock (NV)) Stock Analysis - Insider Trades

Rezolute, Inc. Common Stock (NV) (RZLT) is a publicly traded Healthcare sector company. As of May 21, 2026, RZLT trades at $3.23 with a market cap of $311.99M and a P/E ratio of -3.27. RZLT moved +3.87% today. Year to date, RZLT is +63.87%; over the trailing twelve months it is -18.48%. Its 52-week range spans $1.07 to $11.46. Analyst consensus is buy with an average price target of $6.25. Rallies surfaces RZLT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RZLT stock inside the company?

Recent RZLT insider activity includes Evans Daron bought 10.00K, Hogenhuis Wladimir bought 5.65K, ROBERTS BRIAN KENNETH bought 28.00K, Evans Daron bought 40.00K, and Evans Daron bought 2.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RZLT Key Metrics

Key financial metrics for RZLT
Metric	Value
Price	$3.23
Market Cap	$311.99M
P/E Ratio	-3.27
EPS	$-0.98
Dividend Yield	0.00%
52-Week High	$11.46
52-Week Low	$1.07
Volume	1.51K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-74.41M
Gross Margin	0.00%

Recent RZLT Insider Trades

Evans Daron bought 10.00K (~$28.50K) on Mar 30, 2026.
Hogenhuis Wladimir bought 5.65K (~$9.55K) on Dec 16, 2025.
ROBERTS BRIAN KENNETH bought 28.00K (~$47.60K) on Dec 16, 2025.
Evans Daron bought 40.00K (~$70.64K) on Dec 15, 2025.
Evans Daron bought 2.50K (~$4.46K) on Dec 15, 2025.

Latest RZLT News

Rezolute Logs $16.2M Q3 Loss with $120.3M Cash, Phase 3 Study Shows >50% Hypoglycemia Reduction — May 12, 2026
Rezolute Shows Over 50% Hypoglycemia Reduction in Phase 3 sunRIZE Data — May 1, 2026
Rezolute Presents Phase 3 sunRIZE Data and Post-Hoc Analyses at Pediatric Endocrine Society Annual Meeting — Apr 21, 2026
FDA Encourages Rezolute to Submit sunRIZE Data for Marketing Approval — Mar 24, 2026
Rezolute’s Phase 3 sunRIZE Fails Endpoints, $132.9M Cash and $22.8M Loss — Feb 12, 2026

RZLT Analyst Consensus

6 analysts cover RZLT: 0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.25.

Common questions about RZLT

Who is trading RZLT stock inside the company?: Recent RZLT insider activity includes Evans Daron bought 10.00K, Hogenhuis Wladimir bought 5.65K, ROBERTS BRIAN KENNETH bought 28.00K, Evans Daron bought 40.00K, and Evans Daron bought 2.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RZLT?: Yes. Rallies tracks RZLT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RZLT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RZLT. It does not provide personalized investment advice.